Emyria Ltd
ASX:EMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Emyria Ltd
PP&E Gross
Emyria Ltd
PP&E Gross Peer Comparison
Emyria Ltd
Glance View
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
See Also
What is Emyria Ltd's PP&E Gross?
PP&E Gross
819.8k
AUD
Based on the financial report for Jun 30, 2025, Emyria Ltd's PP&E Gross amounts to 819.8k AUD.
What is Emyria Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
-2%
Over the last year, the PP&E Gross growth was -35%. The average annual PP&E Gross growth rates for Emyria Ltd have been -9% over the past three years , -2% over the past five years .
